The Journal

Recent articles

  • Between a Rock and a Hard Place

    By
    Douglas Isles,
    User

    An actuary by training, Douglas first joined Platinum in 2003 as an investment analyst, having spent some time at the Commonwealth Bank as a product actuary and, prior to that.. More

    03 Jun 2020

    In recent years, investors have crowded into predictable equities that look like bonds, be they defensive companies with stable cash flows or strong growth companies acting as long duration zero-coupon bonds. As bond yields fall, the logic goes that lower discount rates lead to higher equity...

  • Market Update - 29 May 2020

    By
    Andrew Clifford,
    User

    Andrew co-founded Platinum in 1994 as the Deputy Chief Investment Officer, having worked alongside Kerr for several years at Bankers Trust and perfecting the craft of.. More

    29 May 2020

    Our net exposure to markets in the portfolio is often seen as a guide to how we feel about the world, though one must be careful not to confuse a net exposure of 85% in the flagship portfolio, the Platinum International Fund, as indicative of unbridled optimism (94% long, 9% short as at 27 May...

  • Automakers: Anatomy of a Crisis

    Automakers are likely to be among the businesses most acutely impacted by COVID-19. Over the next 12 months, most will likely rack up multi-billion-dollar losses that we will read about on the front pages of the financial press. However, accounting losses only tell half the story. Chief...

  • Market Update - 19 May 2020

    By
    Andrew Clifford,
    User

    Andrew co-founded Platinum in 1994 as the Deputy Chief Investment Officer, having worked alongside Kerr for several years at Bankers Trust and perfecting the craft of.. More

    19 May 2020

    Moderna is a US biotech company that some Platinum funds[1] have owned since its IPO in late 2018 (bought at US$23), and have added since, most notably in a placement early this year (at US$19). Last night, the company announced positive data on its phase one trials for its vaccine ...

  • Biotechs: Proving Prevention Really is Better than the Cure

    By
    Dr Bianca Ogden,
    User

    Molecular biology was Bianca’s first love before she discovered the joys and challenges of investing. After spending some time at Swiss pharmaceuticals company Novartis.. More

    15 May 2020

    The global healthcare sector has undergone significant change over the past 20 years with more to come, largely driven by advances in the dynamic biotech sector. Involved in such things as antibody therapies, protein engineering, gene editing, immunology and diagnostic tools, the biotech...

    share-icon Share
  • Your Pantry: COVID-19 and Beyond

    By 08 May 2020

    Most fast-moving consumer goods (FMCG) companies are reporting unprecedented growth in sales and earnings as their product categories benefit from coronavirus-driven demand. One thing we are watching with interest is what the companies are saying about consumer behaviour during lockdowns, and...